Therapeutic options for pulmonary arterial hypertension (PAH) remain limited because animal models are poorly representative of human PAH, and human in vitro tissue and cell-based assays lack the architectural complexity of the intact organ. We hypothesized that it would be possible to develop a human model of PAH using ex vivo lung perfusion (EVLP) technology and that such a model would serve to both enhance the safety of and expedite early-phase clinical studies for novel PAH therapies. After nationwide consultation, an Australian-first process for the retrieval of human lungs for research was developed. Based on studies in whole animals, a protocol for the establishment of PAH in ex vivo perfused and ventilated lungs using a thromboxane analogue (U-46619, Cayman Chemical) was developed. A 60-year-old female suffered a hypoxic cerebral injury following cardiac arrest. Resuscitation was initially successful; however, a decision to withdraw life-sustaining treatment was made 48 hours later. The family consented to donation after cardiac death, including research. The warm ischemic time was 17 minutes. Initial PaO 2 was 467 mmHg; however, the presence of significant right lung congestion, small pulmonary infarcts, and a pancreatic nodule mandated EVLP. The organs were transported at 4˚C to TPCH, rewarmed, and established on EVLP (CO 4 L/min). After 2.5 hours, EVLP pulmonary edema worsened, and the organs were declined for transplantation. Stable PAH (PVR: 800-900 dyn/s/cm 5 ) was rapidly established using 260 μg U-46619 with minimal circuit metabolism, facilitating the successful safety testing of a novel biologic with PAH activity. In conclusion, we have pioneered the development of a human model of PAH which will accelerate the development of novel therapies.
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Gravity-dependent redistribution of pulmonary perfusion is lost in patients with pulmonary hypertension: a quantitative SPECT/CT study In clinical practice, pulmonary vascular disease (PVD) is detected relatively late in its natural history, when pulmonary hypertension (PHT) occurs. We hypothesized that the normal gravity-dependent redistribution of lung perfusion resulting from postural change is impaired in PHT and may thus have potential for the assessment of PVD. Our aim was to assess the redistribution of pulmonary perfusion between supine and upright positions in patients with precapillary PHT and in controls. Regional pulmonary perfusion in supine and upright positions was obtained by quantitative single-photon emission computed tomography (SPECT) using 99m Tc-macroaggregated albumin. A perfusion redistribution index (PRI) was calculated to quantify the perfusion shift along the cranial-caudal axis between different postures. Regional lung perfusion was evaluated in 14 PHT subjects and 11 controls. Controls displayed the expected cranial-caudal gradient in lung perfusion in upright position (left lung, 0:074 AE 0:056 normalized perfusion counts/cm; right lung, 0:070 AE 0:079 normalized perfusion counts/cm), which became abolished on lying flat. In relation to perfusion redistribution, PHT subjects had markedly reduced PRI with postural change compared to controls (0:44 AE 0:26 vs. 3:71 AE 0:66, P ¼ 0:0002). A cut-off PRI value of 1.5 had sensitivity and specificity of 93% and 82% in separating PHT from control group. On multivariate analysis, the presence of PHT was the only significant predictor of PRI. In conclusion, gravity-dependent redistribution of lung perfusion is markedly diminished in subjects with PHT. This simple, inexpensive, and noninvasive technique may have potential utility for the detection of PVD.
Outcomes of systemic sclerosis patients with exercise-induced pulmonary arterial hypertension treated with advanced therapies Increased pulmonary arterial remodeling has recently been described in the upper lobes, compared with the lower lobes, of patients with severe COPD. However, the relationship between pulmonary arterial remodeling and pulmonary perfusion in patients with COPD has not been established. Histological morphology of muscular pulmonary arteries was performed on COPD explants, using digital image analysis. Pulmonary arterial remodeling was measured as the percentage of wall thickness to vessel diameter (%WT). The lobar perfusion index (LPI) was calculated as the ratio of lobar perfusion to total pulmonary perfusion from technetium-99m ventilation-perfusion (V/Q) scintigraphy. Repeated-measures weighted effects of LPI were calculated for %WT after adjusting for lobar origin and pulmonary arterial size. Five hundred ninety vessels were analyzed from 17 COPD lung transplant patients, with an average (AESEM) %WT of 29.4% (AE1.8%). There was no difference in LPI between the upper and lower lobes. However, the LPI was significantly positively associated with %WT (weighted effect AE SEM: 1:69 AE 0:7, P < 0:05), so that for every 10% increase in LPI, the %WT was estimated to increase by an absolute amount of 1.69%. In conclusion, increased lobar perfusion on V/Q scintigraphy is associated with increased pulmonary arterial remodeling in severe COPD. This positive relationship suggests that increased regional blood flow likely contributes to increased regional pulmonary arterial remodeling in patients with severe COPD. The six-minute walk distance (6MWD) is a validated measure of mortality and morbidity in pulmonary arterial hypertension (PAH). However, the addition of cardiopulmonary measures to a 6MWT may provide further indices of disease severity in PAH, in particular an estimate of oxygen uptake (VO 2 ) and breathing efficiency (BE: V E /VCO 2 ). The purpose of this study was to examine the relationship between disease severity and cardiopulmonary measures during a 6MWT. Prospectively, 42 patients (27 F, 49 AE 18 years) from tertiary PH center completed a 6MWT while gas exchange was simultaneously measured using a portable metabolic cart. Pre-and end-exercise measurements of VO 2 , carbon dioxide production (VCO 2 ), and ventilation (V E ) were determined from 30-second averages. Heart rate (HR), oxygen saturation, and rating of exertion (RPE) were recorded every minute. All patients underwent echocardiography, and standard measurements of right ventricular function were measured. Mean 6MWD was 503 AE 102 m, with mean WHO-FC 2:0 AE 0:34. During the 6MWT there was a significant increase in VO 2 (pre: 6:0 AE 1:3 mL kg −1 min −1 ; end: 14:1 AE 1:6 mL kg −1 min −1 ), V E (pre: 17:0 AE 5:2 L min −1 ; end: 48:4 AE 5:0 L min −1 ), BE (pre: 41:2 AE 7:6, end: 43:2 AE 7:6), HR (pre: 83 AE 14 beats min −1 ; end: 133 AE 18 beats min −1 ), and RPE (pre: 0:3 AE 0:7; end: 4:0 AE 1:4). RVSP was significantly correlated with end-exercise BE (r ¼ 0:49, P < 0:01) and 6MWD (r ¼ À0:34, P < 0:05). This study demonstrates that the addition of cardiopulmonary measures to a 6MWT provides additional information regarding disease severity in PAH and therefore may be a useful tool to assess response to therapies.
An echocardiographic snapshot of right ventricular dysfunction Right ventricular function is an important predictor of mortality and morbidity in pulmonary hypertension (PH). Identifying accurate and reliable echocardiographic parameters for the functional assessment of the right ventricle (RV) still remains a challenge. Our aim was to assess the efficacy of echocardiographic parameters in the assessment of right ventricular dysfunction in patients with advanced PHT as directed by current guidelines. Eighty-two patients (68% F) from a tertiary PAH center-21 IPAH, 3 FPAH, 20 PAH-CHD, 17 PAH-CTD, 7 CTEPH, 4 portopulmonary, and 10 out of proportion PHT-underwent echocardiography with an RVSP > 50 mmHg over a 3-month period by a blinded operator. Mean age of patients was 54:3 AE 17:7 years, mWHO was FC 2:7 AE 0:6, and m6MWT was 404 AE 150:3 m, with 45% prescribed one, 29% two, and 17% triple PAH therapies. Echocardiography confirmed severe PHT with mean RVSP 90:6 AE 24 mmHg, mRA size 25:4 AE 7:6 cm 2 , and 18% trivial, 6% mild, and 2% moderate pericardial effusion and RVD present in 84% of this group. However, the mean TAPSE 18 AE 4:7 mm and mean S′ of 10.8 were preserved within normal limits. Our data support RVSP, RA size, and the presence of pericardial effusion as important predictors but challenge current pulmonary hypertension guidelines in the utility of TAPSE and S′ in the prognosis and monitoring of patients prescribed advanced PH therapies. Further analysis of RV strain patterns and fractional area change within this group is warranted. Patients with iPAH receiving disease-specific therapy are assessed regularly, but noninvasive measures predicting deterioration are needed. We investigated whether clinical deterioration of patients with iPAH could be predicted by echo characteristics. Thirty-five stable patients (7 M, 28 F; age 70 AE 10 [SD] years) with iPAH confirmed on right heart catheter (21 with resting iPAH and 14 with iPAH on exercise [eiPAH]) were followed as outpatients in a community-based specialist practice for a mean of 4:1 AE 1:8 years. All echo parameters, including standard 2D echo measurements, estimated PASP (ePASP) atrial volumes, RV Tei index, and calculated pulmonary vascular resistance (cPVR), were collected prospectively, the present study being a retrospective review of this cohort. Patient deterioration was defined as death; worsening of 6-minute walk test (6MWT) distance, NYHA class, or Borg dyspnea score; or increased drug treatment. Sixteen patients improved clinically, 12 were unchanged, and 7 deteriorated, including 2 patients who died. Two patients were current smokers, and neither deteriorated clinically during follow-up. Patients who deteriorated were older (78 AE 10 vs. 68 AE 10 years, P ¼ 0:04) with more severe PAH at baseline (mPAP: 37 AE 9 vs. 27 AE 11 mmHg, P ¼ 0:025; cPVR: 2:9 AE 1:0 vs. 2:0 AE 0:8 WU, P ¼ 0:04). During follow-up, increasing cPVR was the only echo parameter predicting deterioration (change: 1:4 AE 2:3 vs. 0:0 AE 0:4, P ¼ 0:03).
Patients with eiPAH were younger than those with iPAH (65 AE 2 vs. 73 AE 2 years), with less severe PAH at baseline (mPAP: 17 AE 1 vs. 37 AE 2 mmHg, P < 0:001; cPVR: 1.6 vs. 2:7 AE 0:3 WU, P ¼ 0:004). During follow-up, no patient with eiPAH clinically deteriorated, and when compared with iPAH patients, the echo-derived PASP and 6MWT improved (À2:6 AE 0:7 vs. 12:7 AE 4:4 mmHg, P ¼ 0:005, and 120 AE 17 vs. 64 AE 20 m, P ¼ 0:04, respectively). One-fourth of patients with treated iPAH at rest deteriorated clinically, whereas treated eiPAH patients remained stable.
Deterioration was predicted at baseline by age and PAH severity, but during follow-up only cPVR predicted worsening. The cPVR appears to be a robust measure during follow-up of patients with PAH.
A call for IV therapy for pulmonary artery hypertension (PAH) in New Zealand T McWilliams, K Whyte, A Coverdale, C Stewart, C Wasywich Auckland Regional PAH and New Zealand Heart and Lung Transplant Service, Auckland City Hospital, Auckland, New Zealand Treatment for PAH in New Zealand is tightly restricted for economic reasons, and IV therapy has never been available to patients other than for brief in-hospital use. The only drug registered for IV use is iloprost, and this is funded only in its nebulized form, Ventavis. Dual oral/nebulized combination therapy is funded; however, when this fails, switching drugs and lung transplant (LT), if appropriate, are the only options available to patients. The Auckland Regional PAH Clinic sees around half of all patients in New Zealand on therapy and all patients with PAH being assessed for LT. We wanted to investigate the need for IV therapy in this group by first assessing the severity of patients already on combination therapy (CT) and then developing a criteria for initiating IV therapy. We present the demographics and the 6MW results and hemodynamics of our patients at the start of monotherapy (MT) and CT and the numbers on CT who would be suitable for IV therapy and/or LT. In total, 147 patients with Class I, IV, and V PH (all of whom are eligible for therapy in New Zealand if they have WHO III or IV symptoms) have been under the care of the Auckland Regional service. One hundred eight are female, and mean age at diagnosis is 49 years (SD = 17 years). Mean time to diagnosis was 102 weeks. 52 (35%) had IPAH, 43 (29%) CTD, and 27 (18.2%) had CTEPH. In total, 121 patients have received PH-specific therapy: 72 on MT, 49 on CT, and a further 6 on CCB (calcium channel blocker) therapy. Mean time to combination therapy was 76 weeks. A recent review of this clinic reported a 91% 1-year and 67% 5-year survival. To assess the number of patients eligible for IV therapy if available, we identified 32 of the 49 patients on CT still alive as of January 9, 2012; 13 have died, and 4 have had LT. For these 32 patients (of whom only 12 are LT candidates), the proposed criteria for IV therapy would be persistence of WHO IV, 6MW < 300 m (unless limited by other factors, e.g., gout, obesity, immobility), rising RA, and worsening RHC hemodynamics on combination therapy for 6 months. Clearly, our patients have severe disease at initiation of therapy, and there is a need for IV therapy in New Zealand.
Pharmaceutical Benefits Scheme (PBS)-funded epoprostenol in Australia: are we making optimal use of this therapy? Following the withdrawal from market of the pulmonary arterial hypertension (PAH) drug sitaxsentan in December 2010, patients on sitaxsentan had to be switched to an alternate agent. We assessed the clinical effect of this switch on subsequent six-minute walk distance test (SMWD) and echocardiographic parameters. Pulmonary arterial hypertension patients from St. Vincent's Hospital and the Alfred Hospital who were taking sitaxsentan were retrospectively enrolled in this study (total n ¼ 61). These patients were switched to another endothelin receptor antagonist (ERA), either bosentan or ambrisentan, with some patients combining one of these agents with sildenafil. The inclusion criteria required that patient had been taking the drug for >6 months in order that the regular follow-up SMWD and echocardiogram would be available for assessment (n ¼ 30). Data prior to and after the switch, including pre/post scores based on gender, were analyzed using repeated-measures t tests and repeated-measures ANOVA tests. The pre-and post-6MWD data suggested that over half of the population had experienced some degree of functional decline (16/30), while 12 of 30 patients reported improvement and 2 of 30 remained stable. Furthermore, the mean pre-and postswitch 6MWD scores (388 AE 148 vs. 365 AE 182 m) across the entire population suggested that the switch had resulted in some degree of clinical instability. However, repeated-measures t tests revealed no significant difference between mean SMWD on sitaxsentan and that 6 months after the switch (average decrease of 23 AE 80 m; P ¼ 0:135). Repeatedmeasures ANOVA showed no significant difference in the pre-and postswitch scores in males (n ¼ 4; 514 AE 194 vs. 534 AE 192 m) versus females (n ¼ 26; 366 AE 133 vs. 335 AE 169 m). With regard to the drug therapy used after the switch, repeated-measures ANOVA determined that there was no significant difference in clinical outcomes (P ¼ 0:472; ambrisentan n ¼ 14, bosentan n ¼ 6, bosentan/sildenafil n ¼ 8). Given the small population for the combination of ambrisentan/sildenafil (n ¼ 1) and sildenafil alone (n ¼ 1), these populations were omitted from statistical analysis. Echocardiogram parameters were assessed on a 0-6 semiquantitative scale. Repeated-measures t tests revealed no significant difference in the population between pre-and postswitch echocardiogram results. The statistical analysis evaluated pre-and postswitch mean left atrial size (39:4 AE 6:5 vs. 39:7 AE 6:1 mm), and assessed pre-and postswitch semiquantitative scores for severity of tricuspid regurgitation The 6-minute walk test (6MWT) is reported a safe assessment of exercise capacity in pulmonary arterial hypertension-associated congenital heart disease (PAH-CHD). However, PAH-CHD patients have a marked decrease in arterial oxygen saturation (SpO 2 ) during exercise, which, based on current guidelines, would result in ceasing the 6MWT. Given the clinical value of the 6-minute walk distance (6MWD), many centers continue to undertake 6MWT in PAH-CHD patients, albeit with a marked reduction in end-exercise SaO 2 . To date, there has been no description of the cardiopulmonary response to 6MWT in PAH-CHD. We report gas exchange abnormalities during a 6MWT to challenge current literature in PAH-CHD. A 39-year-old patient born with transposition of the great vessels, with ventricular septal defect and irreversible PAH (mPAP 87 mmHg), WHO-FC II, and on PAH therapy completed a 6MWT while the gas exchange was measured simultaneously (portable metabolic cart; Cortex). SpO 2 was estimated using the average value from two forehead probes. Oxygen carrying capacity (CaO 2 ) was estimated from the resting Hb (17.8 g/dL) and the SaO 2 . The 6MWD was 563 m with no rest breaks. Pre-exercise SaO 2 and rating of exertion (RPE) were 88% and 0 respectively. At the end of the 6MWT, SaO 2 was 42%, RPE was 3, heart rate was 161 bpm, oxygen uptake was 17 mL/kg/min, and breathing efficiency (VE/VCO 2 ) was 43.4. The patient's CaO 2 fell from 20 to 13 mL/100 mL. This PAH-CHD patient had a marked reduction in the CaO 2 during exercise, characterized by an alarming fall in SpO 2 . Despite this, the individual was able to complete the 6MWT and remain remarkably nonbreathless. These data highlight the need to develop specific guidelines for 6MWT in this PAH subgroup. Pulmonary hypertension (PHT) and right ventricular dysfunction (RVD) are important considerations in the management of cardiothoracic (CTS) patients in the ICU. Management involves optimization of oxygenation, ventilation, acid-base balance, volume status, inotrope support, pulmonary vasodilation, and mechanical RV support. Sildenafil, a PDE-5 inhibitor, has been shown to improve exercise capacity, WHO functional class, and hemodynamics in patients with symptomatic Group I PAH. We report our experience in the effectiveness and safety of IV sildenafil in adult CTS patients. Four patients with RVD/PH were prospectively assigned to IV sildenafil: (1) acute PE;
(2) severe PH post-(R) pneumonectomy in lung transplant recipient; (3) RVD post-(L) ventricular device insertion; and (4) RVD post-orthotopic heart transplantation. Patients received standard therapy for RVD: mechanical ventilation, inotropes, and inhaled NO. Hemodynamic and echocardiography parameters were compared pre-and post-sildenafil administration. Median sildenafil dose was 1.6 mg/h (IQR: 0.75-2.5 mg/h). There was a significant reduction in CVP (P ¼ 0:03) on day 2. The reductions in mean arterial pressure (P ¼ 0:07) and heart rate (P ¼ 0:2) were not statistically significant. There were no significant increases in inotrope or vasopressors doses, volume administered, or O 2 requirements. 3 patients survived to hospital discharge, and 1 died in the ICU. Inhaled NO was weaned in all patients except patient 2. In conclusion, IV sildenafil can be an effective and safe adjunct in the management of PH/RVD in the adult ICU, resulting in improvements in RV function and enabled successful wean of NO. More research is required in a larger population before consideration as a standard of care in management of patients with RVD/PH. The tricuspid annular plane systolic excursion (TAPSE) and S′ are validated echocardiography markers of morbidity and mortality in pulmonary arterial hypertension (PAH). We report the concerning anomaly of normalization of quantitative parameters of annular motion in the setting of severe right heart dysfunction (RVD) characterized by the "rocking right ventricle." Our aim was to perform a comparative analysis on imaging modalities in patients with RVD and normal TAPSE and S′. Cardiac MRI, echocardiography RV fractional area change (FAC), and visual assessment of right ventricular (RV) function are compared. Fourteen patients (50% F) from a tertiary PAH center-5 IPAH, 2 FPAH, 3 PAH-CHD, 2 CTEPH, and 2 out-of-proportion PHT-underwent one echocardiogram (including FAC, TAPSE, and S′) with prior cardiac MRI. Mean age of patients was 52:4 AE 17 years, mNYHA class was 2:6 AE 0:5, and m6MWD was 480 AE 166:2 m, with 36% prescribed one, 27% two, and 27% triple PAH therapies. The mRVSP was 98:2 AE 18:4 mmHg, mTAPSE was 19:9 AE 3:7 mm, and mean S′ was 11:8 AE 1:8, with mRA size 27:4 AE 5:5 cm 2 and 21% pericardial effusion. Calculated RV FAC was 18:9% AE 6:6%; normal range was >35%, compared to mRVEDV of 141:7 AE 35 mL (BSA corrected) and RVEF of 32:8% AE 7:3%. In conclusion, the visual assessment of the presence of RVD in PAH has high specificity and correlates with cardiac MRI and FAC change on echocardiography. TAPSE and S′ have poor correlation and are frequently normal in patients with advanced PAH and associated RVD. Visual assessment in PAH patients may have a characteristic appearance with "rocking" of the RV during the cardiac cycle and tricuspid annular motion dissociated from overall RV function.
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